fruquintinib

Drug Overview

Fruquintinib is a selective, small-molecule tyrosine kinase inhibitor (TKI) and a targeted therapy designed to inhibit tumor angiogenesis. It is administered orally for the treatment of refractory metastatic colorectal cancer.

• Generic Name: Fruquintinib
• US Brand Names: Fruzaqla™
• Drug Class: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor
• Route of Administration: Oral
• FDA Approval Status: Approved in November 2023 for previously treated metastatic colorectal cancer.

fruquintinib is an amazing new choice for advanced cancer. Explore how this powerful drug targets tumors to give patients more time.

What Is It and How Does It Work? (Mechanism of Action)

Fruquintinib is a selective, oral tyrosine kinase inhibitor (TKI) and targeted therapy designed to block tumor angiogenesis (new blood vessel formation).

• Molecular Target: It potently inhibits the intracellular kinase domains of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 (VEGFR-1, -2, -3), with high selectivity for VEGFR-2, the primary driver of angiogenesis.
• Blockade of Signaling: By binding to these receptors, fruquintinib prevents their activation by VEGF ligands. This halts the downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways in endothelial cells.
• Result: The inhibition of VEGFR signaling leads to regression of existing tumor vasculature and inhibition of new blood vessel growth. This deprives the tumor of oxygen and nutrients, suppressing tumor growth and metastasis.

FDA-Approved Clinical Indications

Oncological Indications:

• Metastatic Colorectal Cancer (mCRC): For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Non-Oncological Uses:

• None. Fruquintinib is exclusively indicated for oncology.

Dosage and Administration Protocols:

Fruquintinib is administered orally once daily for 21 days, followed by a rest period. Consistent adherence to the schedule is crucial for efficacy.

Renal and Hepatic Dose Adjustments

• Dose Modifications: Dose interruptions and reductions are required to manage toxicity. The recommended dose reductions are sequentially to 4 mg and then to 3 mg once daily. Permanent discontinuation is required for certain severe adverse events.
• Hepatic/Renal Impairment: No starting dose adjustment is needed for mild or moderate hepatic or renal impairment. Use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR 15-29 mL/min/1.73 m²), due to lack of clinical data.

Clinical Efficacy and Research Results

The 2023 FDA approval of fruquintinib was based on the pivotal global Phase 3 FRESCO-2 trial in patients with heavily pretreated metastatic colorectal cancer (mCRC).

• Overall Survival (OS): Treatment with fruquintinib plus best supportive care (BSC) demonstrated a significant improvement in median OS compared to placebo plus BSC: 7.4 months vs. 4.8 months (Hazard Ratio [HR] = 0.66). This represents a 34% reduction in the risk of death.
• Progression-Free Survival (PFS): The benefit in delaying disease progression was even greater, with a median PFS of 3.7 months vs. 1.8 months for placebo (HR = 0.32), equating to a 68% reduction in the risk of progression or death.
• Disease Control: The disease control rate (DCR) was significantly higher with fruquintinib (55.5% vs. 16.1%), confirming its ability to stabilize previously progressing disease.

This established fruquintinib as an effective oral targeted therapy option following standard chemotherapy and biologic agents for mCRC

Safety Profile and Side Effects

Black Box Warning: 

• There is no FDA Black Box Warning for fruquintinib.

Common Side Effects (>10%):

• Hypertension: Very common (incidence >60%). Usually managed with standard antihypertensive therapy.
• Hand-Foot Skin Reaction (HFSR): Palmar-plantar erythrodysesthesia (incidence >40%). Characterized by redness, pain, swelling, and blistering on palms and soles.
• Proteinuria: Common, often detected on routine urinalysis.
• Voice Disorder/Hoarseness.
• Gastrointestinal: Abdominal pain, diarrhea.
• Hematological: Leukopenia, thrombocytopenia.
• General: Fatigue, asthenia.

Serious Adverse Events:

• Hemorrhagic Events: Serious or fatal hemorrhages, including gastrointestinal bleeding, have occurred.
• Hypertensive Crisis: Severe, uncontrolled hypertension.
• Gastrointestinal Perforation: A rare but life-threatening complication.
• Hepatotoxicity: Drug-induced liver injury, including hepatic failure, has been reported.
• Posterior Reversible Encephalopathy Syndrome (PRES).
• Impaired Wound Healing: Therapy should be interrupted prior to elective surgery.

Management Strategies:

• Hypertension: Monitor blood pressure weekly for the first 8 weeks, then at least monthly. Initiate or optimize antihypertensive medication promptly. Temporarily hold fruquintinib for severe hypertension; resume at a reduced dose once controlled.
• Hand-Foot Skin Reaction: Use thick moisturizers, urea-based creams, and wear soft, padded footwear. For Grade 2 or 3 HFSR, dose interruption and subsequent reduction are recommended.
• Proteinuria: Monitor urinalysis regularly. For persistent ≥2 g/24 hours proteinuria, interrupt therapy until improvement, then resume at a reduced dose.
• Bleeding: Permanently discontinue for severe or life-threatening hemorrhage.

Research Areas

Fruquintinib is being investigated in earlier lines of therapy and in novel combinations to expand its utility.

• Combination with Immunotherapy: Preclinical data suggests VEGFR inhibition may modulate the immunosuppressive tumor microenvironment. Several Phase 1b/2 clinical trials are actively exploring fruquintinib in combination with immune checkpoint inhibitors (e.g., sintilimab, tislelizumab) for various solid tumors, including advanced hepatocellular carcinoma and non-small cell lung cancer.
• Expansion into Other Tumor Types: Research is ongoing to evaluate its efficacy in other highly vascularized tumors, such as gastric cancer and soft tissue sarcoma, based on its potent anti-angiogenic mechanism.

Patient Management & Practical Recommendations

Pre-Treatment:

• Blood Pressure Assessment: Establish a baseline blood pressure and control pre-existing hypertension.
• Laboratory Tests: Complete Blood Count (CBC), comprehensive metabolic panel (including liver and renal function tests), and urinalysis.
• Wound Healing: Ensure any elective surgical procedures are completed and wounds are fully healed before initiation.

Precautions During Treatment:

• Rigorous BP Monitoring: Adhere strictly to the schedule for blood pressure checks. Patients should have a home blood pressure monitor and keep a log.
• Skin Care: Proactively initiate a regimen for moisturizing hands and feet. Avoid friction, hot water, and prolonged pressure.
• Bleeding Vigilance: Monitor for signs of bleeding (e.g., unusual bruising, blood in stool or urine, coughing up blood).

Do’s and Don’ts

• DO: Take the capsule at the same time each day, with a full glass of water, with or without food.
• DO: Report new or worsening headaches, vision changes, seizures (signs of PRES), or severe abdominal pain (signs of GI perforation) immediately.
• DO: Inform all healthcare providers (including dentists) that you are taking this drug before any procedure.
• DON’T: Crush, chew, or open the capsules.
• DON’T: Take the medication if you have an unhealed wound from recent surgery.
• DON’T: Become pregnant. Use effective contraception during and for 2 weeks after the final dose. Fruquintinib can cause fetal harm.

Legal Disclaimer

This information is intended for educational purposes for international patients and healthcare professionals and does not constitute medical advice. Treatment protocols must be individualized. Always consult a qualified oncologist for personal medical decisions. Dosing may vary based on patient status and regional guidelines.